Home | Welcome to Contract Pharma   
Last Updated Thursday, April 24 2014
Print

Financial Report: AMRI



By Kristin Brooks



Published February 12, 2014
AMRI
 
4Q Revenues: $67.1 million (flat)

4Q Earnings: $4.5 million (+137%)

FY Revenues: $246.6 million (+9%)

FY Earnings: $12.7 million (loss of $3.8 million FY12)

Comments: Contract revenue for the quarter was a record $59.7 million, up 1%. Royalty revenue in the quarter was $7.4 million, down 9%, and includes royalties from the Allegra products as well as $2.3 million from sales of certain amphetamine salts sold by Actavis. Contract revenue for the year was a record $210.0 million, up 11%, while royalty revenue was $36.6 million, up 2%. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the quarter was $18.4 million, down 12%, with lower revenue in Development / Small Scale Manufacturing, partially offset by higher Discovery Services revenue, and for the year was $77.4 million, up 5%. Large Scale Manufacturing revenue for the quarter was $41.3 million, up 8%, and $132.6 million for the year, up 14%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On